[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60043188D1 - Hitzebeständige umhüllte kolloidale eisenoxide - Google Patents

Hitzebeständige umhüllte kolloidale eisenoxide

Info

Publication number
DE60043188D1
DE60043188D1 DE60043188T DE60043188T DE60043188D1 DE 60043188 D1 DE60043188 D1 DE 60043188D1 DE 60043188 T DE60043188 T DE 60043188T DE 60043188 T DE60043188 T DE 60043188T DE 60043188 D1 DE60043188 D1 DE 60043188D1
Authority
DE
Germany
Prior art keywords
colloidal
heat
compositions
methods
ice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60043188T
Other languages
English (en)
Inventor
Ernest V Groman
Kenneth G Paul
Timothy B Frigo
Howard Bengele
Jerome M Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amag Pharmaceuticals Inc
Original Assignee
Amag Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22436002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60043188(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amag Pharmaceuticals Inc filed Critical Amag Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60043188D1 publication Critical patent/DE60043188D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Ceramic Engineering (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Iron (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Cookers (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
DE60043188T 1999-04-09 2000-03-08 Hitzebeständige umhüllte kolloidale eisenoxide Expired - Lifetime DE60043188D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12857999P 1999-04-09 1999-04-09
PCT/US2000/006047 WO2000061191A2 (en) 1999-04-09 2000-03-08 Heat stable coated colloidal iron oxides

Publications (1)

Publication Number Publication Date
DE60043188D1 true DE60043188D1 (de) 2009-12-03

Family

ID=22436002

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60043188T Expired - Lifetime DE60043188D1 (de) 1999-04-09 2000-03-08 Hitzebeständige umhüllte kolloidale eisenoxide

Country Status (11)

Country Link
US (2) US6599498B1 (de)
EP (1) EP1169062B1 (de)
JP (2) JP5064612B2 (de)
AT (1) ATE446108T1 (de)
CY (1) CY1109527T1 (de)
DE (1) DE60043188D1 (de)
DK (1) DK1169062T3 (de)
ES (1) ES2334555T3 (de)
LU (1) LU92114I2 (de)
PT (1) PT1169062E (de)
WO (1) WO2000061191A2 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US7169618B2 (en) * 2000-06-28 2007-01-30 Skold Technology Magnetic particles and methods of producing coated magnetic particles
DE10046514A1 (de) * 2000-09-15 2002-04-25 Diagnostikforschung Inst Verfahren zur bildlichen Darstellung und Diagnose von Thromben mittels Kernspintomographie unter Verwendung partikulärer Kontrastmittel
US6690962B2 (en) 2000-09-15 2004-02-10 Institut fur Diagnostikforshung GmbH Process for graphic visualization and diagnosis of thrombi by means of nuclear spin tomography with use of particulate contrast media
RU2003121403A (ru) * 2000-12-07 2004-12-27 АД "ЗДРАВЛЬЕ" Фармасеутско-кемийска индустри , Сентар за истразиванье и развой (YU) Полиядерный комплекс fe(iii) с олигомерами пуллулана, способ его получения и фармацевтические препараты на его основе
EP1401508A1 (de) * 2001-06-29 2004-03-31 Biovitrum Ab Verfahren für die bulk-autoklavierung
ATE536993T1 (de) 2002-01-02 2011-12-15 Visen Medical Inc Aminfunktionalisierte superparamagnetisierte nanoteilchen für die synthese von biokonjugaten
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060018835A1 (en) * 2004-04-02 2006-01-26 General Electric Company Nanoparticles with inorganic core and methods of using them
US20060014938A1 (en) * 2004-07-14 2006-01-19 Groman Ernest V Stable aqueous colloidal lanthanide oxides
US20060140867A1 (en) * 2004-12-28 2006-06-29 Helfer Jeffrey L Coated stent assembly and coating materials
ATE515711T1 (de) 2005-05-09 2011-07-15 Gen Hospital Corp Sensoren auf wasserrelaxationsbasis
EP1932009B1 (de) * 2005-08-31 2014-02-12 T2 Biosystems, Inc. Nmr-einrichtung zur detektion von analyten unter beteiligung von magnetischen teilchen
US20070077313A1 (en) * 2005-10-04 2007-04-05 U.S. Pharmaceutical Corporation Toleration iron supplement compositions
EP1973575B1 (de) 2005-12-22 2019-07-24 Visen Medical, Inc. Biokompatibele fluoreszierende metalloxide nanopartikel
AU2013206429B2 (en) * 2006-01-06 2016-04-28 Vifor (International) Ag Methods and compositions for administration of iron
KR101905340B1 (ko) 2006-01-06 2018-10-05 루이트폴드 파머수티컬스, 인코퍼레이티드 철을 투여하기 위한 방법 및 조성물
AU2016205002C1 (en) * 2006-01-06 2020-09-24 Vifor (International) Ag Methods and compositions for administration of iron
NO329127B1 (no) * 2006-09-12 2010-08-30 Epitarget As Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
AU2007317787B2 (en) 2006-11-08 2012-07-12 T2 Biosystems, Inc. NMR systems for in vivo detection of analytes
WO2008127031A1 (en) * 2007-04-12 2008-10-23 Industry-Academic Cooperation Foundation, Yonsei University Magnetic resonance imaging contrast agents comprising zinc-containing magnetic metal oxide nanoparticles
US20120003160A1 (en) * 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
US8421458B2 (en) 2007-09-28 2013-04-16 T2 Biosystems, Inc. NMR diagnostics by means of a plastic sample container
WO2009061481A1 (en) 2007-11-06 2009-05-14 T2 Biosystems, Inc. Small magnet and rf coil for magnetic resonance relaxometry
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
EP2277181B1 (de) * 2008-04-16 2017-08-30 StemCell Technologies Inc. Magnetpartikel
AU2009308841B2 (en) 2008-10-29 2014-07-17 T2 Biosystems, Inc. NMR detection of coagulation time
WO2010091183A2 (en) * 2009-02-04 2010-08-12 The Regents Of The University Of Colorado, A Body Corporate Non-invasive detection of complement-mediated inflammation using cr2-targeted nanoparticles
EP2411039A4 (de) 2009-03-23 2015-05-06 Brigham & Womens Hospital Glycokonjugat-impfstoffe
US8815301B2 (en) 2009-03-25 2014-08-26 Pharmacosmos Holding A/S Stable iron oligosaccharide compound
WO2011005496A2 (en) 2009-06-22 2011-01-13 Massachusetts Eye & Ear Infirmary Islet1 (isl1) and hearing loss
EP2575772A4 (de) 2010-05-26 2014-03-19 Gen Hospital Corp Magnetische nanopartikel
WO2011153331A2 (en) 2010-06-02 2011-12-08 The General Hospital Corporation Optical sensor conjugates for detecting reactive oxygen and/or reactive nitrogen species in vivo
CN106176808A (zh) 2010-10-19 2016-12-07 长春纳米生技公司 金属离子纳米簇组合物
EP3974831A1 (de) 2010-10-22 2022-03-30 T2 Biosystems, Inc. Verfahren zum nachweis eines bakteriums in einer vollblutprobe
US8563298B2 (en) 2010-10-22 2013-10-22 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
US8409807B2 (en) 2010-10-22 2013-04-02 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
CN102086232B (zh) * 2010-12-15 2012-05-23 吕辉 一种多糖铁的制备方法
US9599627B2 (en) 2011-07-13 2017-03-21 T2 Biosystems, Inc. NMR methods for monitoring blood clot formation
CA2843586A1 (fr) 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
US10620205B2 (en) 2011-09-21 2020-04-14 T2 Biosystems, Inc. NMR methods for endotoxin analysis
WO2013078332A1 (en) 2011-11-23 2013-05-30 The General Hospital Corporation Analyte detection using magnetic hall effect
CN104114155B (zh) 2012-01-09 2019-02-15 阿道恰公司 Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液
EP2647389A1 (de) 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetische Nanopartikeldispersion, ihre Herstellung sowie diagnostische und therapeutische Verwendung
WO2013158281A1 (en) 2012-04-20 2013-10-24 T2 Biosystems, Inc. Compositions and methods for detection of candida species
US10274490B2 (en) 2012-06-12 2019-04-30 The General Hospital Corporation Magnetic labeling of bacteria
EP2864051B1 (de) 2012-06-25 2020-09-23 The General Hospital Corporation Sortieren von partikeln unter verwendung von starken magnetfeldern
US9675640B2 (en) * 2012-08-07 2017-06-13 Southwest Research Institute Magnetic calcium phosphate nanoparticles, applications and methods of preparation thereof
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
CA2893591A1 (en) 2012-12-07 2014-06-12 T2 Biosystems, Inc. Methods for monitoring tight clot formation
KR102218494B1 (ko) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
US9370202B2 (en) * 2013-03-15 2016-06-21 LG Bionano, LLC Encapsulated metal ion nanoclusters
EP3560591B1 (de) 2013-10-18 2021-02-17 The General Hospital Corporation Mikrofluidische sortierung unter verwendung von magnetfeldern mit hohem gradienten
US9566216B2 (en) 2013-11-18 2017-02-14 Southwest Research Institute Bone cements containing magnetic calcium phosphate nanoparticles
KR20150078375A (ko) 2013-12-30 2015-07-08 한화케미칼 주식회사 철산화물 나노입자를 포함하는 철결핍증의 예방 또는 치료용 약학 조성물
US10898581B2 (en) 2014-01-16 2021-01-26 The Brigham And Women's Hospital, Inc. Targeted delivery of immunoregulatory drugs
TWI689310B (zh) 2014-07-11 2020-04-01 巨生生醫股份有限公司 治療鐵缺乏症之方法
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US9610582B2 (en) 2014-11-03 2017-04-04 The General Hospital Corporation Combined sorting and concentrating particles in a microfluidic device
CN105597105B (zh) * 2014-11-19 2020-03-10 连云港润众制药有限公司 一种菲立莫妥的制备方法
EP3274053A4 (de) 2015-03-23 2018-12-05 The Brigham and Women's Hospital, Inc. Tolerogene nanopartikel zur behandlung von diabetes mellitus
US10258647B2 (en) 2015-09-01 2019-04-16 Particle Dynamics International, Llc Iron-polysaccharide complexes and methods for the preparation thereof
AU2017210033B2 (en) 2016-01-21 2022-09-29 T2 Biosystems, Inc. NMR methods and systems for the rapid detection of bacteria
CN105708805A (zh) * 2016-01-28 2016-06-29 山西普德药业股份有限公司 一种还原型羧烷基葡聚糖铁及其制备方法
CN105708792A (zh) * 2016-01-28 2016-06-29 山西普德药业股份有限公司 一种还原型羧烷基葡聚糖铁注射液及其制备方法
CN105616372A (zh) * 2016-01-28 2016-06-01 山西普德药业股份有限公司 一种还原型羧烷基葡聚糖铁片剂
TR201703251A2 (tr) 2017-03-03 2017-07-21 Berna Buelbuel Kansizliğin transdermal yoldan tedavi̇si̇nde kullanilacak demi̇r oksi̇t nanokri̇stalleri̇ i̇çeren solüsyon
CN108403716B (zh) * 2018-06-25 2021-11-05 博瑞生物医药（苏州）股份有限公司 一种超顺磁氧化铁的制备方法
AU2020221821A1 (en) 2019-02-13 2021-08-26 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2885393A (en) 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US2862920A (en) 1956-06-07 1958-12-02 Ohio Commw Eng Co Ferrous carboxymethyl dextran
US2856398A (en) 1956-06-15 1958-10-14 Ohio Commw Eng Co Carboxymethyl dextran-iron complexes
US3000872A (en) 1956-06-15 1961-09-19 Ohio Commw Eng Co Preparation of carboxymethyl dextran-iron complexes
US2856366A (en) 1956-07-30 1958-10-14 Ohio Commw Eng Co Stable alkaline metal solutions containing carboxymethyl dextran
US3151107A (en) 1960-12-22 1964-09-29 Central Pharmacal Company Water-soluble iron complexes of carboxymethyl dextran
GB1019513A (en) * 1961-08-07 1966-02-09 Chemicals Inc Iron dextran complexes
US3234209A (en) * 1963-09-13 1966-02-08 Chemicals Inc Process for making iron hydrogenated dextran
JPS5913521B2 (ja) 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4180567A (en) 1977-09-02 1979-12-25 Pharmachem Corporation Iron preparations and methods of making and administering the same
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
ES2030667T3 (es) 1985-12-20 1992-11-16 Syntex (U.S.A.) Inc. Metodo de separacion de particulas.
US5076950A (en) 1985-12-20 1991-12-31 Syntex (U.S.A.) Inc. Magnetic composition for particle separation
US5055288A (en) 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5262176A (en) 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US5160726A (en) 1990-02-15 1992-11-03 Advanced Magnetics Inc. Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
GB8808305D0 (en) * 1988-04-08 1988-05-11 Nycomed As Compositions
JP2726520B2 (ja) * 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体
EP0506880A1 (de) * 1989-12-22 1992-10-07 Molecular Bioquest, Inc. Teilchen mit organo-metallischem überzug zur verwendung in abscheidungen
GB9416767D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
EP0783325B2 (de) * 1994-09-27 2004-03-31 Amersham Health AS Kontrastmittel
WO1998008899A1 (fr) * 1996-08-30 1998-03-05 Meito Sangyo Kabushiki Kaisha Composite contenant un derive de polysaccharide et un oxyde metallique magnetique
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
DK173138B1 (da) * 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma

Also Published As

Publication number Publication date
JP5064612B2 (ja) 2012-10-31
US7553479B2 (en) 2009-06-30
DK1169062T3 (da) 2010-01-25
LU92114I2 (fr) 2013-12-14
ATE446108T1 (de) 2009-11-15
US6599498B1 (en) 2003-07-29
JP2002541218A (ja) 2002-12-03
WO2000061191A9 (en) 2001-06-21
ES2334555T3 (es) 2010-03-12
EP1169062A2 (de) 2002-01-09
CY1109527T1 (el) 2014-08-13
PT1169062E (pt) 2009-12-17
WO2000061191A2 (en) 2000-10-19
US20030225033A1 (en) 2003-12-04
WO2000061191A3 (en) 2001-05-25
JP2011046752A (ja) 2011-03-10
EP1169062B1 (de) 2009-10-21

Similar Documents

Publication Publication Date Title
DE60043188D1 (de) Hitzebeständige umhüllte kolloidale eisenoxide
PL366421A1 (en) Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in nmr diagnosis and radiodiagnosis and radiotherapy
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001243327A1 (en) Novel quinoline ligands and metal complexes for diagnosis and therapy
AU5540400A (en) Bicyclic polyaminoacid metal complexes, method for preparing same and use in medical imaging
AU2001296724A1 (en) Microelectronic magnetic structure, device including the structure, and methods of forming the structure and device
EP1212760A4 (de) Supraleitende magnetspule
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU8015600A (en) Respiratory nitric oxide meter
GB0204115D0 (en) Metal complexes comprising A 2,6-Diacylpyride-ligand and their use in the polymerzation of ethylene
GB2355537B (en) Magnetic resonance tomography device with vibration-isolated outer cover
AU2002245169A1 (en) Fullerene (c60)-based x-ray contrast agent for diagnostic imaging
WO2002044342A3 (en) Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
EP1088993A4 (de) Ausgangsschalldämpfer und geschlossener elektrischer kompressor
AU7754901A (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
EP0778563A3 (de) Magnetoresistive Vorrichtung mit eingebauter Leitergeometrie, um einen wesentlich konstanten Stromfluss zu schaffen für Verbesserte magnetische Stabilität
AU3221195A (en) Macrocyclic chelants, their chelates and uses thereof in the diagnostic field
EP1197760A3 (de) Unterdrückung der Wirkung von verbleibender Magnetisierung in der bildgebenden magnetischen Resonanz
WO2003013616A8 (en) Ionic and non-ionic radiographic contrast agents for use in combined x-ray and nuclear magnetic resonance diagnostics
AU2002241628A1 (en) Cobalt-porphyrin complexes and use thereof as an anti-obesity agent
AU1660201A (en) Biglycan and related therapeutics and methods of use
HUP0300601A3 (en) Use of bile acid derivatives conjugated with metal ion chelated complexes for the diagnostic assessment of microvascular permeability
HUP0203065A3 (en) Use of nitric oxide for the treatment of airway constriction
MY124005A (en) Composite magnetic body, and electromagnetic interference suppressing body using the same.
AU4452900A (en) Compositions and methods for the therapy and diagnosis of prostate cancer

Legal Events

Date Code Title Description
8363 Opposition against the patent
R065 Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: FERUMOXYTOL; REGISTRATION NO/DATE: EU/1/12/774/001-002 20120615

Spc suppl protection certif: 122012000059

Filing date: 20120814

Expiry date: 20200309

Effective date: 20120917